Advertisement

The role of microRNAs in the development, regulation, and treatment of atrial fibrillation

  • Oxana Galenko
  • Victoria Jacobs
  • Stacey Knight
  • Madisyn Taylor
  • Michael J. Cutler
  • Joseph B. Muhlestein
  • John L. Carlquist
  • Kirk U. Knowlton
  • T. Jared BunchEmail author
MULTIMEDIA REPORT
  • 29 Downloads

Abstract

Background

MicroRNAs (miRNA)s regulate expression of genes involved in various processes including cardiac automaticity, conduction, excitability, and fibrosis and therefore may provide a diagnostic utility to identify high-risk patients for atrial fibrillation (AF). In this study, we tested the hypothesis that specific profiles of circulating miRNAs can identify patients with AF and can also help to identify patients at high risk of AF recurrence after ablation.

Methods

Two patient populations were studied: 140 AF cases (93 paroxysmal and 47 persistent) and 50 healthy controls, and 141 AF ablation cases with (n = 86) and without (n = 55) 1-year recurrence. Assessment of several previously identified AF-associated plasma miRNAs (21, 29a, 133a, 133b, 150, 328) was performed with TaqMan assays, using synthetic miRNAs as standards.

Results

The AF cases compared to the healthy controls were older and were more often male and hypertensive. After multivariate adjustment, higher miRNA-21 levels significantly decreased the risk of AF (OR = 0.93 per fmol/μl (95% CI = 0.89–0.98, p = 0.007)). There were no significant differences in circulating miRNAs between the AF subtypes of persistent and paroxysmal. Among the AF ablation cases, miRNA-150 was lower for those with AF recurrences at 1 year (adjusted OR = 0.98 per 500,000 fmol/μl; 95% CI = 0.965, 0.998; p = 0.039).

Conclusions

Decreased circulating miRNA-21 is associated with AF, but not with AF subtypes, suggestive that molecular mechanisms responsible for the onset and progression of the AF may be different. Circulating miRNA-150 was significantly associated with a reduction in 1-year AF recurrence post ablation suggestive of adverse structural and electrical remodeling as recurrence mechanisms.

Keywords

Atrial fibrillation Ablation Outcomes Atrium MicroRNA Fibrosis Outcomes 

Notes

Acknowledgements

The authors thank Matt Grover, Lizzy Stauder, and Johnny Thrang for their assistance with samples processing.

Funding

This study received funding from the Intermountain Research and Medical Foundation Grant.

Compliance with ethical standards

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was a retrospective design with stored serum used for analysis. All patients provided consent for the use of their serum and medical records for research purposes. The study was approved by the IRB.

Conflict of interest

Oxana Galenko: none

Victoria Jacobs: none

Stacey Knight: none

Madisyn Taylor: none

Michael J. Cutler: none

Joseph B. Muhlestein: none

John Carlquist: none

Kirk Knowlton: none

T. Jared Bunch: major, Boehringer Ingelheim research grant

Supplementary material

10840_2018_495_MOESM1_ESM.docx (30 kb)
Supplemental Table 1 (DOCX 29 kb)
10840_2018_495_MOESM2_ESM.docx (326 kb)
Supplemental Figure 1 (DOCX 326 kb)

References

  1. 1.
    Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114:119–25.Google Scholar
  2. 2.
    Chinitz JS, Castellano JM, Kovacic JC, Fuster V. Atrial fibrillation, stroke, and quality of life. Ann N Y Acad Sci. 2012;1254:140–50.CrossRefGoogle Scholar
  3. 3.
    Lip GY, Fauchier L, Freedman SB, Van Gelder I, Natale A, Gianni C, et al. Atrial fibrillation. Nat Rev Dis Primers. 2016;2:16016.Google Scholar
  4. 4.
    Kottkamp H. Human atrial fibrillation substrate: towards a specific fibrotic atrial cardiomyopathy. Eur Heart J. 2013;34:2731–8.CrossRefGoogle Scholar
  5. 5.
    Wang Z, Lu Y, Yang B. MicroRNAs and atrial fibrillation: new fundamentals. Cardiovasc Res. 2011;89:710–21.CrossRefGoogle Scholar
  6. 6.
    Santulli G, Iaccarino G, De Luca N, Trimarco B, Condorelli G. Atrial fibrillation and microRNAs. Front Physiol. 2014;5:15.CrossRefGoogle Scholar
  7. 7.
    McDonald JS, Milosevic D, Reddi HV, Grebe KS, Algeciras-Schimnich A. Analysis of circulating microRNA: preanalytical and analytical challenges. Clin Chem. 2011;57:833–40.CrossRefGoogle Scholar
  8. 8.
    Kroh EM, Parkin RK, Mitchell PS, Tewari M. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods. 2010;50:298–301.CrossRefGoogle Scholar
  9. 9.
    Xiao J, Z-C, Elinor PT, Liang D, Zhang H, Liu Y, et al. MicroRNA-134 as a potential plasma biomarker for the diagnosis of acute pulmonary embolism. J Transl Med. 2011;9:159.Google Scholar
  10. 10.
    Adachi T, Nakanishi M, Otsuka Y, Nishimura K, Hirokawa G, Goto Y, et al. Plasma miR-499 as a biomarker of acute myocardial infarction in humans. Clin Chem. 2010;56:1183–5.Google Scholar
  11. 11.
    Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci. 2008;105(30):10513–8.Google Scholar
  12. 12.
    Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.CrossRefGoogle Scholar
  13. 13.
    Laterza OF, Lim L, Garrett-Engele PW, Vlasakova K, Muniappa N, Tanaka WK, et al. Plasma MicroRNAs as sensitive and specific biomarkers of tissue injury. Clin Chem. 2009;55:1977–83.Google Scholar
  14. 14.
    McManus DD, Tanriverdi K, Lin H, Esa N, Kinno M, Mandapati D, et al. Plasma microRNAs are associated with atrial fibrillation and change after catheter ablation (the miRhythm study). Heart Rhythm. 2015;12:3–10.Google Scholar
  15. 15.
    Liu Z, Zhou C, Liu Y, Wang S, Ye P, Miao X, et al. The expression levels of plasma micoRNAs in atrial fibrillation patients. PLoS One. 2012;7:e44906.Google Scholar
  16. 16.
    Nishi H, Sakaguchi T, Miyagawa S, Yoshikawa Y, Fukushima S, Saito S, et al. Impact of microRNA expression in human atrial tissue in patients with atrial fibrillation undergoing cardiac surgery. PLoS One. 2013;8:e73397.Google Scholar
  17. 17.
    D’Alessandra Y, Pompilio G, Capogrossi MC. Letter by D’Alessandra et al regarding article, “Circulating microRNA-208b and microRNA-499 reflect myocardial damage in cardiovascular disease”. Circ Cardiovasc Genet. 2011;4(1):e7.CrossRefGoogle Scholar
  18. 18.
    Adam O, Lohfelm B, Thum T, Gupta SK, Puhl SL, Schafers HJ, et al. Role of miR-21 in the pathogenesis of atrial fibrosis. Basic Res Cardiol. 2012;107:278.Google Scholar
  19. 19.
    Kumarswamy R, Volkmann I, Thum T. Regulation and function of miRNA-21 in health and disease. RNA Biol. 2011;8:706–13.CrossRefGoogle Scholar
  20. 20.
    Barwari T, Eminaga S, Armstrong PC, Chan MV, Lu R, Barallobre-Barreiro J, et al. Abstract 19935: MicroRNA-21 regulates transforming growth factor beta-1 release from platelets: a novel mechanism for the anti-fibrotic effects of microRNA-21 inhibition. Circulation. 2017;136:A19935–5.Google Scholar
  21. 21.
    Noferesti SS, Sohel MMH, Hoelker M, Salilew-Wondim D, Tholen E, Looft C, et al. Controlled ovarian hyperstimulation induced changes in the expression of circulatory miRNA in bovine follicular fluid and blood plasma. J Ovarian Res. 2015;8(81):81.Google Scholar
  22. 22.
    Deng P, Chen L, Liu Z, Ye P, Wang S, Wu J, et al. MicroRNA-150 inhibits the activation of cardiac fibroblasts by regulating c-Myb. Cell Physiol Biochem. 2016;38:2103–22.Google Scholar
  23. 23.
    Devaux Y, Vausort M, McCann GP, Zangrando J, Kelly D, Razvi N, et al. MicroRNA-150: a novel marker of left ventricular remodeling after acute myocardial infarction. Circ Cardiovasc Genet. 2013;6:290–8.Google Scholar
  24. 24.
    Zeller T, Keller T, Ojeda F, Reichlin T, Twerenbold R, Tzikas S, et al. Assessment of microRNAs in patients with unstable angina pectoris. Eur Heart J. 2014;35:2106–14.Google Scholar
  25. 25.
    Zawada AM, Zhang L, Emrich IE, Rogacev KS, Krezdorn N, Rotter B, et al. MicroRNA profiling of human intermediate monocytes. Immunobiology. 2017;222:587–96.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Oxana Galenko
    • 1
  • Victoria Jacobs
    • 1
  • Stacey Knight
    • 1
    • 2
  • Madisyn Taylor
    • 1
  • Michael J. Cutler
    • 1
  • Joseph B. Muhlestein
    • 1
    • 2
  • John L. Carlquist
    • 1
  • Kirk U. Knowlton
    • 1
    • 2
  • T. Jared Bunch
    • 1
    • 3
    • 4
    Email author
  1. 1.Intermountain Medical Center Heart InstituteMurrayUSA
  2. 2.Department of Internal MedicineUniversity of UtahSalt Lake CityUSA
  3. 3.Department of Internal MedicineStanford UniversityPalo AltoUSA
  4. 4.Intermountain Medical Center Heart Institute, Intermountain Medical CenterSalt Lake CityUSA

Personalised recommendations